Potentials of phenolic molecules of natural origin and their derivatives as anti-HIV agents

Biotechnology Annual Review

Volumn 13, Issue , 2007, Pages 223-264

  Hassan Khan, Mahmud Tareq ^a,b   Ather, Arjumand ^c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY CHITTAGONG   (Bangladesh)

^b Institute of Medical Biology   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

anti HIV; catechin; chalcone; chemogenomics; coumarin; docking; flavonoids; gallate; HIV; HIV promoter; integrase; natural products' databases; neural network; phenolics; protease; Protein Databank.; reverse transcriptase; virtual screening

Indexed keywords

ABACAVIR; ACACIA MELLIFERA EXTRACT; ANTHRAQUINONE DERIVATIVE; ANTIRETROVIRUS AGENT; CAFFEIC ACID DERIVATIVE; CHLOROGENIC ACID; CICHORIC ACID; DIDANOSINE; DNA; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FLAVANONE DERIVATIVE; FOSCARNET; LAMIVUDINE; MAYTENUS BUCHANANI EXTRACT; MAYTENUS SENEGALENSIS EXTRACT; MELIA AZEDARACH EXTRACT; PHENOL DERIVATIVE; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; RHUS NATALENSIS EXTRACT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSMARINIC ACID; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THEAFLAVIN 3,3' DIGALLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNONIA JUGALIS EXTRACT; ZALCITABINE; ZIDOVUDINE;

ACACIA; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANTIVIRAL ACTIVITY; ARTIFICIAL NEURAL NETWORK; BIODIVERSITY; CAUSE OF DEATH; CELL FUSION; COMPUTER MODEL; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; FUNCTIONAL GENOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; MAYTENUS; MAYTENUS BUCHANANI; MAYTENUS SENEGALENSIS; MEDICAL RESEARCH; MELIA AZEDARACH; MOLECULAR DOCKING; NONHUMAN; PHARMACOGENOMICS; POISON IVY; PROTEIN DEGRADATION; PYGEUM; REVERSE TRANSCRIPTION; REVIEW; TRADITIONAL MEDICINE; VERNONIA; VIROGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION;

ANTI-HIV AGENTS; BIOLOGICAL PRODUCTS; DRUG COMPOUNDING; PHENOLS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548571884     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(07)13009-X     Document Type: Review

References (145)

1. Cos P., Maes L., Berghe D.V., Hermans N., Pieters L., and Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Product 67 (2004) 284-293
2. Wang W.K., Chen M.Y., Chuang C.Y., Jeang K.T., and Huang L.M. Molecular biology of human immunodeficiency virus type 1. J Microbiol Immunol Infect 33 3 (2000) 131-140
3. Pani A., Loi A.G., Mura M., Marceddu T., La Colla P., and Marongiu M.E. Targeting HIV: old and new players. Curr Drug Targets Infect Disord 2 1 (2002) 17-32
4. Bukrinskaya AG, HIV-1 assembly and maturation. Arch Virol 2004;149(6):1067-1082.
5. Bannwarth S., and Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr HIV Res 3 1 (2005) 61-71
6. Nielsen M.H., Pedersen F.S., and Kjems J. Molecular strategies to inhibit HIV-1 replication. Retro Virology 2 1 (2005) 10
7. Manfredi R., and Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem 13 20 (2006) 2369-2384
8. Yu D., Morris-Natschke S.L., and Lee K.H. New developments in natural products-based anti-AIDS research. Med Res Rev 27 1 (2007) 108-132
9. Khan M.T., Ather A., Thompson K.D., and Gambari R. Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res 67 2 (2005) 107-119
10. Pomerantz R.J., and Horn D.L. Twenty years of therapy for HIV-1 infection. Nat Med 9 7 (2003) 867-873
11. Bailly F, Cotelle P, Anti-HIV activities of natural antioxidant caffeic acid derivatives: toward an antiviral supplementation diet. Curr Med Chem 2005;12(15): 1811-1818, and references cited therein.
12. Barbaro G. HIV-associated cardiomyopathy etiopathogenesis and clinical aspects. Herz 30 6 (2005) 486-492
13. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 5 4 (2005) 337-343
14. Barbaro G., Lucchini A., and Barbarini G. Highly active antiretroviral therapy in HIV-associated pulmonary hypertension. Minerva Cardioangiol 53 2 (2005) 153-154
15. Barbaro G., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11 14 (2005) 1805-1843
16. Atta ur R., Harvey K., and Siddiqui R.A. Interleukin-8: An autocrine inflammatory mediator. Curr Pharm Des 5 4 (1999) 241-253
17. Vlietinck A.J., Bruyne T.D., Apers S., and Pieters L.A. Planta Med 64 (1998) 97
18. Matthee G., Wright A.D., and Konig G.M. HIV reverse transcriptase inhibitors of natural origin. Planta Med 65 6 (1999) 493-506
19. Bedoya L.M., Sanchez-Palomino S., Abad M.J., Bermejo P., and Alcami J. Anti-HIV activity of medicinal plant extracts. J Ethnopharmacol 77 1 (2001) 113-116
20. Ng T.B., Huang B., Fong W.P., and Yeung H.W. Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. Life Sci 61 10 (1997) 933-949
21. Schinazi R.F., Chu C.K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L.S., Beach J.W., Choi W.B., and Yeola S. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 36 3 (1992) 672-676
22. Schinazi R.F., Mead J.R., and Feorino P.M. Insights into HIV chemotherapy. AIDS Res Hum Retroviruses 8 6 (1992) 963-990
23. Schinazi RF, In: Chu, C. K. C., H. G. Ed.; Natural Products As Antiviral Agents; Plenum Press: New York, 1992, pp.1-30.
24. Jung M., Lee S., and Kim H. Recent studies on natural products as anti-HIV agents. Curr Med Chem 7 6 (2000) 649-661
25. Asres K., and Bucar F. Anti-HIV activity against immunodeficiency virus type 1 (HIV-I) and type II (HIV-II) of compounds isolated from the stem bark of Combretum molle. Ethiop Med J 43 1 (2005) 15-20
26. Asres K., Seyoum A., Veeresham C., Bucar F., and Gibbons S. Naturally derived anti-HIV agents. Phytother Res 19 7 (2005) 557-581
27. Kanyara J.N., and Njagi E.N. Anti-HIV-1 activities in extracts from some medicinal plants as assessed in an in vitro biochemical HIV-1 reverse transcriptase assay. Phytother Res 19 4 (2005) 287-290
28. el-Mekkawy S., Meselhy M.R., Kusumoto I.T., Kadota S., Hattori M., and Namba T. Inhibitory effects of Egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase. Chem Pharm Bull 43 (1995) 641-648
29. Park J.C., Hur J.M., Park J.G., Hatano T., Yoshida T., Miyashiro H., Min B.S., and Hattori M. Inhibitory effects of Korean medicinal plants and camelliatannin H from Camellia japonica on human immunodeficiency virus type 1 protease. Phytotherapy Res 16 (2002) 422-426
30. Park J.C., Kim S.C., Choi M.R., Song S.H., Yoo E.J., Kim S.H., Miyashiro H., and Hattori M. Anti-HIV protease activity from rosa family plant extracts and rosamultin from Rosa rugosa. J Med Food 8 1 (2005) 107-109
31. Bessong P.O., Obi C.L., Andreola M.L., Rojas L.B., Pouysegu L., Igumbor E., Meyer J.J., Quideau S., and Litvak S. Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase. J Ethnopharmacol 99 1 (2005) 83-91
32. Paskaleva E.E., Lin X., Li W., Cotter R., Klein M.T., Roberge E., Yu E.K., Clark B., Veille J.C., Liu Y., Lee D.Y., and Canki M. Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme. AIDS Res Ther 3 (2006) 15
33. Sangma C., Chuakheaw D., Jongkon N., Saenbandit K., Nunrium P., Uthayopas P., and Hannongbua S. Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai medicinal plants database: a combined docking with neural networks approach. Comb Chem High Throughput Screening 8 5 (2005) 417-429
34. Alves C.N., Pinheiro J.C., Camargo A.J., Ferreira M.M.C., Romero R.A.F., and da Silva A.B.F. A multiple linear regression and partial least squares study of flavonoid compounds with anti-HIV activity. J Mol Struct: THEOCHEM 541 1-3 (2001) 81-88
35. Sangma C., Chuakheaw D., Jongkon N., Saenbandit K., Nunrium P., Uthayopas P., and Hannongbua S. Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai medicinal plants database: a combined docking with neural networks approach. Comb Chem High Throughput Screen 8 5 (2005) 417-429
36. Sechi M., Sannia L., Carta F., Palomba M., Dallocchio R., Dessi A., Derudas M., Zawahir Z., and Neamati N. Design of novel bioisosteres of beta-diketo acid inhibitors of HIV-1 integrase. Antivir Chem Chemother 16 1 (2005) 41-61
37. Debnath A.K. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J Med Chem 46 21 (2003) 4501-4515
38. Guichou J.F., Viaud J., Mettling C., Subra G., Lin Y.L., and Chavanieu A. Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem 49 3 (2006) 900-910
39. Kumar V., Sardana S., and Madan A.K. Predicting anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones: computational approach using reformed eccentric connectivity index. J Mol Model (Online) 10 5-6 (2004) 399-407
40. Renner S., Ludwig V., Boden O., Scheffer U., Gobel M., and Schneider G. New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model. Chembiochem 6 6 (2005) 1119-1125
41. Varnek A., and Solov'ev V.P. "In silico" design of potential anti-HIV actives using fragment descriptors. Comb Chem High Throughput Screen 8 5 (2005) 403-416
42. Vilar S., Estrada E., Uriarte E., ;Santana L., and Gutierrez Y. In silico studies toward the discovery of new anti-HIV nucleoside compounds through the use of TOPS-MODE and 2D/3D connectivity indices. 2. Purine derivatives. J Chem Inf Model 45 2 (2005) 502-514
43. von Grotthuss M., Koczyk G., Pas J., Wyrwicz L.S., and Rychlewski L. Ligand.Info small-molecule meta-database. Comb Chem High Throughput Screen 7 8 (2004) 757-761
44. Min B.S., Tomiyama M., Ma C.M., Nakamura N., and Hattori M. Kaempferol acetylrhamnosides from the rhizome of Dryopteris crassirhizoma and their inhibitory effects on three different activities of human immunodeficiency virus-1 reverse transcriptase. Chem Pharm Bull (Tokyo) 49 5 (2001) 546-550
45. Lin Y.M., Anderson H., Flavin M.T., Pai Y.H., Mata-Greenwood E., Pengsuparp T., Pezzuto J.M., Schinazi R.F., Hughes S.H., and Chen F.C. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60 9 (1997) 884-888
46. Pengsuparp T., Cai L., Constant H., Fong H.H., Lin L.Z., Kinghorn A.D., Pezzuto J.M., Cordell G.A., Ingolfsdottir K., Wagner H., and Hughes S.H. Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase. J Nat Prod 58 7 (1995) 1024-1031
47. Kwon H.C., Jung C.M., Shin C.G., Lee J.K., Choi S.U., Kim S.Y., and Lee K.R. A new caffeoyl quinic acid from aster scaber and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. Chem Pharm Bull (Tokyo) 48 11 (2000) 1796-1798
48. Kim H.J., Woo E.R., Shin C.G., and Park H. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod 61 (1998) 145-148
49. Ma C., Nakamura N., Hattori M., Kakuda H., Qiao J., and Yu H. Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia. J Nat Prod 63 2 (2000) 238-242
50. Beier R.C., and Oertli E.H. Psoralen and other linear furocoumarins as phytoalexins in celery. Phytochemistry 22 (1993) 2595-2597
51. Afek U., Sztejnberg A., and Carmely S. 6,7-Dimethoxycoumarin, a citrus phytoalexin conferring resistance against Phytophthora gummosis. Phytochemistry 25 (1986) 1855-1856
52. Zaat S.A.J., van Brussel A.A.N., and Tak T. Flavonoids induce Rhizobium leguminosarum to produce nodDABC gene-related factors that cause thick, short roots and root hair responses on common vetch. J Bacteriol 169 (1987) 3388-3391
53. Laks P.E., and Pruner M.S. Flavonoid biocides: structure/activity relations of flavonoid phytoalexin analogues. Phytochemistry 28 (1989) 87-91
54. Snyder B.A., and Nicholson R.L. Synthesis of phytoalexins in sorghum as a site-specific response to fungal ingress. Science 248 (1990) 1637-1639
55. Kitamura K., Honda M., Yoshizaki H., Yamamoto S., Nakane H., Fukushima M., Ono K., and Tokunaga T. Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res 37 (1998) 131-140
56. Xu H.X., Wan M., Dong H., But P.P.H., and Foo L.Y. Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol Pharm Bull 23 (2000) 1072-1076
57. Likhitwitayawuid K., Sritularak B., Benchanak K., Lipipun V., Mathew J., and Schinazi R.F. Phenolics with antiviral activity from Millettia erythrocalyx and Artocarpus lakoocha. Nat Prod Res 19 2 (2005) 177-182
58. Reddy V.L., Reddy S.M., Ravikanth V., Krishnaiah P., Goud T.V., Rao T.P., Ram T.S., Gonnade R.G., Bhadbhade M., and Venkateswarlu Y. A new bis-andrographolide ether from Andrographis paniculata nees and evaluation of anti-HIV activity. Nat Prod Res 19 3 (2005) 223-230
59. Dixon R.A. The phytoalexin response: elicitation signaling and control of host gene expression. Bioll Rev 61 (1986) 239-291
60. Nahrstedt A, The significance of secondary metabolites for interactions between plants and insects, Planta Med 1990;55:333-338, and references cited therein.
61. Robbins R. Medical and nutritional aspects of citrus bioflavonoids. In: Nagy S., and Attaway J. (Eds). Citrus Nutrition and Quality (1980), American Chemistry Society, Washington, DC 43-59
62. Matsubara Y., Kumamoto H., and Iizuka Y. Structure and hypotensive effect of flavonoid glycosides in Citrus unshiu peelings. Agric Biol Chem 49 (1985) 909-914
63. Robak J., and Gryglewski R.J. Flavonoids are scavengers of superoxide anions. Biochem Pharmacol 37 (1988) 837-841
64. Stolk L.M.L., and Siddiqui A.H. Minireview: biopharmaceutics, pharmacokinetics and pharmacology of psoralens. Gen Pharmacol 19 (1988) 649-653
65. Jacobs M., and Rubery P.H. Naturally occurring auxin transport regulators. Science 241 (1988) 346-349
66. Anonymous, United States Department of Agriculture. Agricultural Research Service website (http://www.ars.usda.gov/is/np/phenolics/intro.htm). 1999.
67. Liu J.-S., and Li L. Kadsulignans L-N, three dibenzocyclooctadiene lignans from Kadsura coccinea. Phytochemistry 38 1 (1995) 241-245
68. Kashiwada Y., Aoshima A., Ikeshiro Y., Chen Y.P., Furukawa H., Itoigawa M., Fujioka T., Mihashi K., Cosentino L.M., Morris-Natschke S.L., and Lee K.H. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. Bioorg Med Chem 13 2 (2005) 443-448
69. Zhang S.Y., Meng L., Gao W.Y., Song N.N., Jia W., and Duan H.Q. Advances on biological activities of coumarins. Zhongguo Zhong Yao Za Zhi 30 6 (2005) 410-414
70. Liu S., Lu H., Zhao Q., He Y., Niu J., Debnath A.K., Wu S., and Jiang S. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723 1-3 (2005) 270-281
71. Mahmood N., Piacente S., Burke A., Khan A., and Pizza C. Antiviral Chem Chemother 8 (1997) 70-74
72. Yamaguchi K., Honda M., Ikigai H., Hara Y., and Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Research 53 (2002) 19-34
73. Nair PM, Kandaswami C, Mahajan S, Nair HN, Chawda R, Shanahan T and Schwartz SA, Grape seed extract proanthocyanidins downregulate HIV-one entry coreceptors, CCRtwob, CCRthree and CCRfive gene expression by normal peripheral blood mononuclear cells. Biol Res 2002;35:421-431.
74. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., and Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266 5193 (1994) 1981-1986
75. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. Nucleic Acids Res 28 1 (2000) 235-242
76. David C., Rowley M., Hansen S.T., Rhodes D., Christoph A., Sotriffer H., Ni J., Andrew McCammon F.D., and Bushman W.F. Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg Med Chem 10 (2002) 3619-3625
77. Tewtrakul S., Nakamura N., Hattori M., Fujiwara T., and Supavita T. Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory Activities. Chem Pharm Bull 50 5 (2002) 630-635
78. Mazumder A., Neamati N., Sunder S., Schulz J., Pertz H., Eich E., and Pommier Y. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 40 (1997) 3057-3063
79. McDougall B., King P.J., Wu B.W., Hostomsky Z., Reinecke M.G., and Robinson Jr. W.E. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 42 1 (1998) 140-146
80. Lin Z., Neamati N., Zhao H., Kiryu Y., Turpin J.A., Aberham C., Strebel K., Kohn K., Witvrouw M., Pannecouque C., Debyser Z., De Clercq E., Rice W.G., Pommier Y., and Burke Jr. T.R. Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem 42 8 (1999) 1401-1414
81. Min B.-S., Tomiyama M., Ma C.-M., Nakamura N., and Hattori N. Kaempferol acetylrhamnosides from the rhizome of Dryopteris crassirhizoma and their inhibitory effects on three different activities of human immunodeficiency virus-1 reverse transcriptase. Chem Pharm Bull 49 5 (2001) 546-550
82. Hopkins A.L., Ren J., Milton J., Hazen R.J., Chan J.H., Stuart D.I., and Stammers D.K. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J Med Chem 47 24 (2004) 5912-5922
83. Kostova I. Coumarins as inhibitors of HIV reverse transcriptase. Curr HIV Res 4 3 (2006) 347-363
84. Ahn M.-J., Yoon K.-D., Min S.-Y., Lee J.S., Kim J.H., Kim T.G., Kim S.H., Kim N.-G., Huh H., and Kim J. Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins from the Brown Alga Ecklonia Cava. Biol Pharm Bull 27 4 (2004) 544-547
85. Anonymous, Encyclopedia of Chinese Materia Medica (Zhon Yao Dai Zi Ten). Jiangsu New Medical College, Ed.; Shanghai Science and Technology Publishers: Shanghai 1977, 2342.
86. Li Y.S., Wang Z.T., Zhang M., Luo S.D., and Chen J.J. A new pinoresinol-type lignan from Ligularia kanaitizensis. Nat Prod Res 19 2 (2005) 125-129
87. Uchiumi F., Hatano T., Ito H., Yoshida T., and Tanuma S.-I. Transcriptional suppression of the HIV promoter by natural compounds. Antiviral Res 58 (2003) 89-98
88. Mizuno T., Uchino K., Toukairin T., Tanabe A., Nakashima H., Yamamoto N., and Ogawara H. Inhibitory effect of tannic acid sulfate and related sulfates on infectivity, cytopathic effect, and giant cell formation of human immunodeficiency virus. Planta Med 58 (1992) 535-539
89. Nakashima H., Murakami T., Yamamoto N., Sakagami H., Tanuma S., Hatano T., Yoshida T., and Okuda T. Inhibition of human immunodeficiency viral replication by tannins and related compounds. Antiviral Res 18 (1992) 91-103
90. Uchiumi F., Maruta H., Inoue J., Yamamoto T., and Tanuma S. Inhibitory effect of tannic acid on human immunodeficiency virus promoter activity induced by 12-O-tetra decanoylphorbol-13-acetate in Jurkat T-cells. Biochem Biophys Res Commun 220 (1996) 411-417
91. Aoki K., Maruta H., Uchiumi F., Hatano T., Yoshida T., and Tanuma S. A macrocircular ellagitannin, oenothein B, suppresses mouse mammary tumor gene expression via inhibition of poly(ADP-ribose) glycohydrolase. Biochem Biophys Res Commun 210 (1995) 329-337
92. Harris C.J., and Stevens A.P. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 11 19-20 (2006) 880-888
93. Tlk 286. Drugs R D 2004;5(2):116-118.
94. Agrafiotis D.K., Lobanov V.S., and Salemme F.R. Combinatorial informatics in the post-genomics ERA. Nat Rev Drug Discov 1 5 (2002) 337-346
95. Ashton G.H., McGrath J.A., and South A.P. Strategies to identify disease genes. Drugs Today 38 4 (2002) 235-244
96. Birault V., Harris C.J., Le J., Lipkin M., Nerella R., and Stevens A. Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits. Curr Med Chem 13 15 (2006) 1735-1748
97. Bleicher K.H. Chemogenomics: bridging a drug discovery gap. Curr Med Chem 9 23 (2002) 2077-2084
98. Bredel M., and Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5 4 (2004) 262-275
99. Byvatov E., and Schneider G. Support vector machine applications in bioinformatics. Appl Bioinformatics 2 2 (2003) 67-77
100. Eguchi M., McMillan M., Nguyen C., Teo J.L., Chi E.Y., Henderson Jr. W.R., and Kahn M. Chemogenomics with peptide secondary structure mimetics. Comb Chem High Throughput Screen 6 7 (2003) 611-621
101. Eguchi Y. [Chemogenomics]. Nippon Yakurigaku Zasshi 125 6 (2005) 365-371
102. Fielden M.R., Pearson C., Brennan R., and Kolaja K.L. Preclinical drug safety analysis by chemogenomic profiling in the liver. Am J Pharmacogenom 5 3 (2005) 161-171
103. Fradera X., and Mestres J. Guided docking approaches to structure-based design and screening. Curr Top Med Chem 4 7 (2004) 687-700
104. Gagna C.E., Winokur D., and Clark Lambert W. Cell biology, chemogenomics and chemoproteomics. Cell Biol Int 28 11 (2004) 755-764
105. Guba W. Chemogenomics strategies for G-protein coupled receptor hit finding. Ernst Schering Res Found Workshop 58 (2006) 21-29
106. Huang Y., and Sadee W. Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. Drug Discov Today 8 8 (2003) 356-363
107. Jacoby E. Chemogenomics: drug discovery's panacea?. Mol Biosyst 2 5 (2006) 218-220
108. Jacoby E., Schuffenhauer A., Popov M., Azzaoui K., Havill B., Schopfer U., Engeloch C., Stanek J., Acklin P., Rigollier P., Stoll F., Koch G., Meier P., Orain D., Giger R., Hinrichs J., Malagu K., Zimmermann J., and Roth H.J. Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Curr Top Med Chem 5 4 (2005) 397-411
109. Jimonet P., and Jager R. Strategies for designing GPCR-focused libraries and screening sets. Curr Opin Drug Discov Dev 7 3 (2004) 325-333
110. Klabunde T., and Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 3 10 (2002) 928-944
111. Klabunde T., and Jager R. Chemogenomics approaches to G-protein coupled receptor lead finding. Ernst Schering Res Found Workshop 58 (2006) 31-46
112. Kley N., Ivanov I., and Meier-Ewert S. Genomics and proteomics tools for compound mode-of-action studies in drug discovery. Pharmacogenomics 5 4 (2004) 395-404
113. Kubinyi H. Chemogenomics in drug discovery. Ernst Schering Res Found Workshop 58 (2006) 1-19
114. Li Q., and Xu W. Novel anticancer targets and drug discovery in post genomic age. Curr Med Chem Anticancer Agents 5 1 (2005) 53-63
115. Mestres J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr Opin Drug Discov Dev 7 3 (2004) 304-313
116. Mestres J. Representativity of target families in the Protein Data Bank: impact for family-directed structure-based drug discovery. Drug Discov Today 10 23-24 (2005) 1629-1637
117. Miller G.G., and Voronina T.A. [Perspective technologies for drug design]. Antibiot Khimioter 50 2-3 (2005) 52-63
118. Savchuk N.P., Balakin K.V., and Tkachenko S.E. Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr Opin Chem Biol 8 4 (2004) 412-417
119. Scapin G. Protein kinase inhibition: different approaches to selective inhibitor design. Curr Drug Targets 7 11 (2006) 1443-1454
120. Shen J., Xu X., Cheng F., Liu H., Luo X., Shen J., Chen K., Zhao W., Shen X., and Jiang H. Virtual screening on natural products for discovering active compounds and target information. Curr Med Chem 10 21 (2003) 2327-2342
121. Shokat K., and Velleca M. Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Discov Today 7 16 (2002) 872-879
122. ter Haar E., Walters W.P., Pazhanisamy S., Taslimi P., Pierce A.C., Bemis G.W., Salituro F.G., and Harbeson S.L. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery. Mini Rev Med Chem 4 3 (2004) 235-253
123. Vieth M., Higgs R.E., Robertson D.H., Shapiro M., Gragg E.A., and Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 1697 1-2 (2004) 243-257
124. Vivanco F., Lopez-Bescos L., Tunon J., and Egido J. [Proteomics and cardiovascular disease]. Rev Esp Cardiol 56 3 (2003) 289-302
125. Zheng X.F., and Chan T.F. Chemical genomics: a systematic approach in biological research and drug discovery. Curr Issues Mol Biol 4 2 (2002) 33-43
126. Caron P.R., Mullican M.D., Mashal R.D., Wilson K.P., Su M.S., and Murcko M.A. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol 5 4 (2001) 464-470
127. Berman H.M., Bhat T.N., Bourne P.E., Feng Z., Gilliland G., Weissig H., and Westbrook J. The Protein Data Bank and the challenge of structural genomics. Nat Struct Biol 7 Suppl (2000) 957-959
128. Yu D., Wild C.T., Martin D.E., Morris-Natschke S.L., Chen C.H., Allaway G.P., and Lee K.H. The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. Expert Opin Investig Drugs 14 6 (2005) 681-693
129. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Adda N., Rozenbaum W., and Capeau J. Diabetes and Metabolism 25 3 (1999) 383-392
130. Kreis W., Kaplan M.H., Freeman J., Sun D.K., and Sarin P.S. Inibition of HIV replication by hyssop officinalis extracts. Antiviral Res 14 6 (1990) 323-337
131. Leighton F., Cuevas A., Guasch V., Perez D.D., Strobel P., San Martin A., Urzua U., Diez M.S., Foncea R., Castillo O., Mizon C., Espinoza M.A., Urquiaga I., Rozowski J., Maiz A., and Germain A. Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs Exp Clin Res 25 (1999) 133-141
132. Lappara J., Michaud J., and Masqualier J. Pharmacokinetic study of flavanolic oligomers. J Plant Med Phytotherarpy 11 (1977) 133-142
133. Parsons A.B., Lopez A., Givoni I.E., Williams D.E., Gray C.A., Porter J., Chua G., Sopko R., Brost R.L., Ho C.H., Wang J., Ketela T., Brenner C., Brill J.A., Fernandez G.E., Lorenz T.C., Payne G.S., Ishihara S., Ohya Y., Andrews B., Hughes T.R., Frey B.J., Graham T.R., Andersen R.J., and Boone C. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 3 (2006) 611-625
134. Aquaro S., Calio R., Balestra E., Bagnarelli P., Cenci A., Bertoli A., Tavazzi B., Di Pierro D., Francesconi M., Abdelahad D., and Perno C.F. Clinical implications of HIV dynamics and drug resistance in macrophages. J Biol Regul Homeost Agents 12 1-2 Suppl (1998) 23-27
135. Charvat T.T., Lee D.J., Robinson W.E., and Chamberlin A.R. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase. Bioorg Med Chem 14 13 (2006) 4552-4567
136. Olsuf'eva E.N., and Preobrazhenskaia M.N. [Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics]. Bioorg Khim 32 4 (2006) 339-359
137. Olszewski A., Sato K., Aron Z.D., Cohen F., Harris A., McDougall B.R., Robinson Jr. W.E., Overman L.E., and Weiss G.A. Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. Proc Natl Acad Sci USA 101 39 (2004) 14079-14084
138. Sun Z., Chen B., Zhang S., and Hu C. Four new eudesmanes from Caragana intermedia and their biological activities. J Nat Prod 67 12 (2004) 1975-1979
139. Richter S., Parolin C., Gatto B., Del Vecchio C., Brocca-Cofano E., Fravolini A., Palu G., and Palumbo M. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 48 5 (2004) 1895-1899
140. Stalmeijer E.H., Van Rij R.P., Boeser-Nunnink B., Visser J.A., Naarding M.A., Schols D., and Schuitemaker H. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 78 6 (2004) 2722-2728
141. Hanna L. Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. Beta 12 2 (1999) 8-9
142. de Baar M.P., Janssens W., de Ronde A., Fransen K., Colebunders R., Kestens L., van der Groen G., and Goudsmit J. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses 16 14 (2000) 1385-1394
143. Wang L.X., Heredia A., Song H., Zhang Z., Yu B., Davis C., and Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 93 10 (2004) 2448-2457
144. Vlietinck A.J., and Vanden Berghe D.A. Can ethnopharmacology contribute to the development of antiviral drugs?. J Ethnopharmacol 32 1-3 (1991) 141-153
145. De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res 7 5B (1987) 1023-1038